In vivo studies using unilateral and bilateral melanoma models demonstrated that OXA&anti-PD-L1@MMP-gel could effectively inhibit local and distant tumor growth, trigger systemic antitumor immune responses, alleviate toxic and side effects, and prolong survival. The gene discussed is CD274; the disease is neoplasm.